Seattle Genetics Reports Second Quarter 2015 Financial Results

Go back to Seattle Genetics Reports Second Quarter 2015 Financial Results

Cowen Raises Price Target on Seattle Genetics (SGEN) Following 2Q15

July 31, 2015 8:46 AM EDT

Cowen reiterated a Market Perform rating on Seattle Genetics (NASDAQ: SGEN), and raises the price target to $40.50 (from $34.00), following 2Q15 results. SGEN posted Adcetris sales of $55.1M for 2Q15, ahead of consensus $50.9M estimates.

Analyst Boris Peaker commented, "SGEN reported 2Q15... More

Seattle Genetics (SGEN) Misses Q2 EPS by 12c, Offers Outlook

July 30, 2015 4:11 PM EDT

Seattle Genetics (NASDAQ: SGEN) reported Q2 EPS of ($0.38), $0.12 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $77.1 million versus the consensus estimate of $77.97 million.

2015 Financial Outlook

Seattle Genetics anticipates that 2015 revenues from ADCETRIS net product... More